Study title: Double-blind, randomized, multi-centre, crossover, placebo-controlled pilot study OXC is indicated for use in treatment of partial seizures in adults and pediatric patients ≥6 years of age. This is a pilot study to assess its efficacy in outpatient children and adoloscents with behavioural disorders
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Behavior and Behavior Mechanisms | |||||
| Brands: Please see report, Please see report | |||||
| MAH holders: Please see report, Please see report | |||||
| Assessment: | |||||
| Active substance: OXACARBAZEPINE | |||||
| ATC code: N03AF02 | |||||
| Document link: oxacarbazepine-TRI476BES04 Art45 Listing 2011.xls | |||||
| Document date: 2011-09-22 | |||||
| Study number: CTRI476BES04 | |||||
| EudraCT number: | |||||
| Scope of study: CLINICAL | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | Y | Y | |